<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22354567</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>09</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-2592</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>32</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of clinical immunology</Title>
                <ISOAbbreviation>J Clin Immunol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Fatal outcome despite full lympho-hematopoietic reconstitution after allogeneic stem cell transplantation in atypical ataxia telangiectasia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>438-40</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10875-012-9654-7</ELocationID>
            <Abstract>
                <AbstractText>Allogeneic hematopoietic stem cell transplantation (HSCT) has not been a therapeutic option in ataxia telangiectasia (AT) due to overwhelming toxicity of conditioning in the context of the global DNA repair deficiency. Furthermore HSCT is unable to cure neurological involvement of AT. We report on a Turkish child with a Hyper IgM phenotype disorder, in which clinical aspects of AT were absent and thus, AT not diagnosed. He was transplanted with a reduced toxicity, but full intensity conditioning regimen comprising treosulfan, fludarabine and ATG. The peritransplant period was uneventful and the patient was discharged at day +57. 8 months after HSCT, the patient developed hepatopathy with monoclonal gammopathy of unclear significance and died due to hepatic failure and encephalopathy at the age of 32 months. Post mortem high throughput sequencing revealed a mutation in the ATM gene.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ghosh</LastName>
                    <ForeName>Sujal</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine Universit채t D체sseldorf, Medical Faculty, 40225, D체sseldorf, Germany. sujal.ghosh@med.uni-duesseldorf.de</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schuster</LastName>
                    <ForeName>Friedhelm R</ForeName>
                    <Initials>FR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Binder</LastName>
                    <ForeName>Vera</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Niehues</LastName>
                    <ForeName>Tim</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baldus</LastName>
                    <ForeName>Stephan E</ForeName>
                    <Initials>SE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seiffert</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Laws</LastName>
                    <ForeName>Hans-J체rgen</ForeName>
                    <Initials>HJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Borkhardt</LastName>
                    <ForeName>Arndt</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meisel</LastName>
                    <ForeName>Roland</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>02</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>J Clin Immunol</MedlineTA>
            <NlmUniqueID>8102137</NlmUniqueID>
            <ISSNLinking>0271-9142</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D001260" MajorTopicYN="N">Ataxia Telangiectasia</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006501" MajorTopicYN="N">Hepatic Encephalopathy</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007136" MajorTopicYN="N">Immunoglobulins</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014184" MajorTopicYN="Y">Transplantation, Homologous</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>01</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>2</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>2</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>9</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22354567</ArticleId>
            <ArticleId IdType="doi">10.1007/s10875-012-9654-7</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Biol Blood Marrow Transplant. 2011 Dec;17(12):1783-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21658461</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Scand J Immunol. 2012 Mar;75(3):350-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22017423</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Birth Defects Orig Artic Ser. 1975;11(1):421-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">125117</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pediatr. 1999 Jun;134(6):786-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10356154</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2011 Apr 21;117(16):4367-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21325599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pediatr. 2004 Apr;144(4):505-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15069401</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arch Dis Child. 2009 Jun;94(6):448-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19224889</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2004 Jul 15;104(2):572-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15044255</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Oncol Rep. 2010 Nov;12(6):383-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20963522</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pediatr Hematol Oncol. 2010 Jan;32(1):e28-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20051774</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Investig Allergol Clin Immunol. 2010;20(5):442-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20945614</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
